CASSAVA SCIENCES INC

Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.

SAVA | US

Overview

Corporate Details

ISIN(s):: US69562K5065 (+1 more)
LEI:
Country:: United States of America
Address:: 6801 N CAPITAL OF TEXAS HIGHWAY, 78731 AUSTIN
Website:: https://www.cassavasciences.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for Central Nervous System (CNS) disorders. The company's lead drug candidate is simufilam, a proprietary, investigational oral small molecule designed to modulate the activity of the filamin A (FLNA) protein, a key regulator in neuronal development. Cassava's primary development program is advancing simufilam as a potential therapy for tuberous sclerosis complex (TSC)-related epilepsy, supported by preclinical data showing a reduction in seizure activity. The company is also exploring the potential application of simufilam for other CNS indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CASSAVA SCIENCES INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CASSAVA SCIENCES INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CASSAVA SCIENCES INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Lavipharm S.A. Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.	Greece	LAVI
	LB PHARMACEUTICALS INC Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.	United States of America	LBRX
	Legend Biotech Corp Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.	United States of America	LEGN
	LENZ Therapeutics, Inc. Develops a prescription eye drop for presbyopia, the age-related loss of near vision.	United States of America	LENZ
	Lexaria Bioscience Corp. Biotech firm with patented technology improving oral drug delivery and absorption.	United States of America	LEXX
	Lexeo Therapeutics, Inc. Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.	United States of America	LXEO
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN
	Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX